Funding · Seed · 29 September 2026
52North raises £3.2m led by Macmillan Ventures
52North has raised £3.2m in a seed round, led by Macmillan Ventures. A private investor, Cedars Sinai Intellectual Property Company, Cancer Research Horizons, University of Cambridge also took part. A finger-prick blood test that flags chemotherapy patients at risk of neutropenic sepsis.
✓ Verified · checked against the published source, 2 Nov 2026. What this means
70thRound size percentile, 23 seed rounds
Press report
Company52North
StageSeed
SectorHealthTech
Based inCambridge
InvestorsMacmillan Ventures, Cedars Sinai Intellectual Property Company, Cancer Research Horizons, University of Cambridge, OKG Capital, Innovate UK and 1 individual investor, named when you sign in
SourcePress · confidence highView source ↗
Your note on 52North
Sign in to keep private notes on this company.
If this is your company
Hide the valuation estimate straight away, add your investors, or tell us something's wrong. We check every change.